Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Ecancermedicalscience. 2018 Oct 25;12:879. doi: 10.3332/ecancer.2018.879. eCollection 2018.

High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease.

Author information

1
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil.
2
AC Camargo Cancer Center, São Paulo, Brazil.

Abstract

Background:

Patients with carcinoid syndrome (CS) may present carcinoid heart disease (CHD) but prognostic factors are not entirely understood.

Patients and Methods:

Retrospective study of patients with metastatic neuroendocrine tumours (NETs) and CS and/or abnormal 24-hour-urinary 5-hydroxiindolacetic acid. CHD was defined as moderate to severe tricuspid or pulmonary regurgitation in the echocardiogram.

Results:

The frequency of CHD among 42 patients was 38% (95% confidence interval [CI]: 23%-54%). CHD was associated with higher volume of liver metastases (odds ratio [OR] 13.86, 95% CI: 2.57-74.68, p = 0.002). Time from CS symptoms to NET diagnosis was borderline significant (p = 0.08). When CHD was defined as at least mild tricuspide regurgitation, the frequency of CHD was 45% and it was associated with cardiovascular comorbidities (OR: 6.58, 95% CI: 1.09; 39.78, p = 0.040).

Conclusion:

CHD was frequent among patients with CS, significantly associated with high liver tumour burden, and likely linked to the history of cardiovascular disease and longer time of CS.

KEYWORDS:

carcinoid heart; carcinoid syndrome; metastases; neuroendocrine tumours

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center